Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model.

Lifshitz V, Weiss R, Benromano T, Kfir E, Blumenfeld-Katzir T, Tempel-Brami C, Assaf Y, Xia W, Wyss-Coray T, Weiner HL, Frenkel D.

Neurobiol Aging. 2012 Feb;33(2):432.e1-432.e13. doi: 10.1016/j.neurobiolaging.2011.01.006. Epub 2011 Mar 2.

2.

TGF-β1 affects endothelial cell interaction with macrophages and T cells leading to the development of cerebrovascular amyloidosis.

Weiss R, Lifshitz V, Frenkel D.

Brain Behav Immun. 2011 Jul;25(5):1017-24. doi: 10.1016/j.bbi.2010.11.012. Epub 2010 Nov 26.

PMID:
21112386
3.

Scavenger receptor A deficiency accelerates cerebrovascular amyloidosis in an animal model.

Lifshitz V, Weiss R, Levy H, Frenkel D.

J Mol Neurosci. 2013 May;50(1):198-203. doi: 10.1007/s12031-012-9909-z. Epub 2012 Oct 30.

PMID:
23108486
4.

A nasal proteosome adjuvant activates microglia and prevents amyloid deposition.

Frenkel D, Puckett L, Petrovic S, Xia W, Chen G, Vega J, Dembinsky-Vaknin A, Shen J, Plante M, Burt DS, Weiner HL.

Ann Neurol. 2008 May;63(5):591-601. doi: 10.1002/ana.21340.

5.

Molecular and functional dissection of TGF-beta1-induced cerebrovascular abnormalities in transgenic mice.

Buckwalter M, Pepper JP, Gaertner RF, Von Euw D, Lacombe P, Wyss-Coray T.

Ann N Y Acad Sci. 2002 Nov;977:87-95. Review.

PMID:
12480736
6.

Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease.

Ongali B, Nicolakakis N, Lecrux C, Aboulkassim T, Rosa-Neto P, Papadopoulos P, Tong XK, Hamel E.

Am J Pathol. 2010 Dec;177(6):3071-80. doi: 10.2353/ajpath.2010.100339. Epub 2010 Nov 18.

7.

Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy.

Fisher M, Vasilevko V, Passos GF, Ventura C, Quiring D, Cribbs DH.

Stroke. 2011 Nov;42(11):3300-3. doi: 10.1161/STROKEAHA.111.626655. Epub 2011 Sep 8.

8.

Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease.

Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L.

Nature. 1997 Oct 9;389(6651):603-6.

PMID:
9335500
10.
11.

Insulin-degrading enzyme deficiency accelerates cerebrovascular amyloidosis in an animal model.

Lifshitz V, Benromano T, Weiss R, Blanga-Kanfi S, Frenkel D.

Brain Behav Immun. 2013 May;30:143-9. doi: 10.1016/j.bbi.2012.12.003. Epub 2012 Dec 19.

PMID:
23257117
12.

Alzheimer's disease-like cerebrovascular pathology in transforming growth factor-beta 1 transgenic mice and functional metabolic correlates.

Wyss-Coray T, Lin C, von Euw D, Masliah E, Mucke L, Lacombe P.

Ann N Y Acad Sci. 2000 Apr;903:317-23.

PMID:
10818521
13.

Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.

Wilcock DM, Colton CA.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):50-64. Review.

14.

Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone.

Nicolakakis N, Aboulkassim T, Aliaga A, Tong XK, Rosa-Neto P, Hamel E.

J Cereb Blood Flow Metab. 2011 Jan;31(1):200-11. doi: 10.1038/jcbfm.2010.78. Epub 2010 Jun 23.

15.

Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity.

Bales KR, O'Neill SM, Pozdnyakov N, Pan F, Caouette D, Pi Y, Wood KM, Volfson D, Cirrito JR, Han BH, Johnson AW, Zipfel GJ, Samad TA.

Brain. 2016 Feb;139(Pt 2):563-77. doi: 10.1093/brain/awv313. Epub 2015 Oct 22.

PMID:
26493635
16.

Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Frenkel D, Maron R, Burt DS, Weiner HL.

J Clin Invest. 2005 Sep;115(9):2423-33. Epub 2005 Aug 11.

18.

TGF-β1 factor in the cerebrovascular diseases of Alzheimer's disease.

Zhang X, Huang WJ, Chen WW.

Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5178-5185. Review.

19.
20.

Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy.

Vasilevko V, Passos GF, Quiring D, Head E, Kim RC, Fisher M, Cribbs DH.

Ann N Y Acad Sci. 2010 Oct;1207:58-70. doi: 10.1111/j.1749-6632.2010.05786.x. Review.

Supplemental Content

Support Center